Propionic Acidemia Market - Top Companies and Manufacturers

  • Report ID: 5773
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Companies Dominating the Propionic Acidemia Landscape

    • Cardiva Grifols SA
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    •  CSL Behring
    •  Octapharma AG
    • Sanquin
    • Kedrion SpA
    • Shire
    • China Biologic Products Holdings Inc.
    • Teva Pharmaceuticals
    • Wellona Pharma
    • Merck
    • AdvaCare Pharma

Browse Key Market Insights with Data Illustration:

In the News

  • In May 2023, Moderna, Inc, a biotechnology company pioneering courier RNA (mRNA) therapeutics and immunizations, expressed that an unique announcing on between times information from the Stage I/II trial of mRNA-3927, an investigational mRNA treatment for propionic acidemia has been acknowledged for introduction at the 2023 American Society of Quality + Cell Treatment Yearly Assembly being held May 16-20, 2023 in Los Angeles, CA.
  • In Eminent 2022, BridgeBio Pharma expressed the Dosing of the Primary Understanding within the Stage I Trial of BBP-671, a Potential best-in-class treatment for propionic acidemia and methylmalonic acidemia (MMA)BBP-671 is an investigational verbal treatment expecting to extend CoA levels by allosterically balancing pantothenate kinases, key proteins within the CoA biosynthesis pathway. 

Author Credits:  Rajrani Baghel


  • Report ID: 5773
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing awareness about propionic acidemia and increasing prevalence of propionic acidemia are some of the major factors anticipated to drive the growth of the propionic acidemia market.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2024 - 2036.

The major players in the market are of China Biologic Products Holdings Inc., Teva Pharmaceuticals, Wellona Pharma, Merck, AdvaCare Pharma, and others.

The L-carnitine segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample